MSAC - Meeting 28-29 March 2018

Medical Services Advisory Committee - Applications Considered

• 1353 – Measurement of Calprotectin as marker of bowel inflammation
• 1372.1 - MRI of the liver for patients with colorectal carcinoma (CRC) with suspected hepatic metastases or patients with suspected hepatocellular carcinoma (HCC) for the purposes of staging
• 1376.1 - 70 gene signature (MammaPrint) for use in breast cancer to quantify the risk of disease recurrence and predict adjuvant chemotherapy benefit
• 1434 - Anti Müllerian hormone testing
• 1435 - Processing and cryopreservation of male and female gonadal tissue and gametes prior to or after gonadotoxic treatment to preserve fertility for the Future (Part B)
• 1440.1 - PD-L1 testing for access to pembrolizumab in treatment naïve patients with locally advanced or metastatic non-small cell lung cancer
• 1449 - Genetic testing for Alport Syndrome
• 1460 - Blue Light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-invasive bladder cancer (NMIBC)
• 1467 – Obstetric MRI
• 1475 - Ablative fractional laser resurfacing for burn scar treatment